Pitavastatin

• CAS: 147526-32-7
• Catalog Number: ACM147526327
• Category: Main Products
• Molecular Weight: 421.46
• Molecular Formula: C25H24FNO4

Case Study

Multiple Mechanisms of Action of Pitavastatin in Improving Atherosclerosis

Davignon, Jean. British journal of clinical pharmacology, 2012, 73(4), 518-535.

Pitavastatin is a new synthetic lipophilic statin with several pharmacodynamic and pharmacokinetic properties that differ from other statins, which may account for its potential pleiotropic effects in reducing cardiovascular risk factors. This work explored the major pleiotropic effects of pitavastatin on endothelial function, vascular inflammation, oxidative stress, and thrombosis.
It can be known from clinical trials, as well as in vitro and animal studies, that pitavastatin works by decreasing LDL-C and triglycerides, but has many other functions as well. They include rises in high-density lipoprotein cholesterol, drops in platelet activation markers, improvements in cardiac, renal and endothelial function, and reductions in endothelial stress, lipoprotein oxidation and finally reductions in atherosclerotic symptoms and symptoms. Some study cases include:
· Endothelial function: After 6 months of pitavastatin treatment, coronary artery disease (CAD) patients had significantly higher fasting and postprandial forearm blood flow in postischemic reactive hyperemia (P < 0.05), but not in control group.
· Oxidative stress: Plasma urocortin concentrations risen in 15 healthy male volunteers who received pitavastatin (2 mg/day-1) for 4 weeks. Endothelial cells make urocortin which prevents reactive oxygen species.
· Oxidation of the lipoproteins: During pitavastatin treatment for type 2 diabetes, markers of oxidative stress are lower as well as cardiovascular and ankle vascular index.

Pitavastatin for the Prevention of Cardiovascular Disease in HIV-Infected Individuals

Grinspoon, Steven K., et al. New England Journal of Medicine, 2023, 389(8), 687-699.

Individuals infected with human immunodeficiency virus (HIV) have an increased risk of cardiovascular disease. This work evaluated the effect of pitavastatin for the prevention of cardiovascular disease in HIV-infected individuals. During a mean follow-up of 5.1 years, participants infected with HIV who received pitavastatin had a lower risk of major adverse cardiovascular events than participants who received placebo.
· Methods of evaluation
In this phase 3 trial, 7769 HIV-infected individuals at low to moderate risk of cardiovascular disease who were receiving antiretroviral therapy were randomly assigned to daily pitavastatin calcium (at a dose of 4 mg) or placebo. The primary outcome was the occurrence of major adverse cardiovascular events.
· Results of evaluation
In terms of major adverse cardiovascular events, the incidence rate was 4.81 per 1,000 person-years for the pitavastatin group, compared to 7.32 per 1,000 person-years in the placebo group, resulting in a hazard ratio of 0.65 (95% confidence interval [CI], 0.48 to 0.90; P=0.002). Muscle-related symptoms were reported by 91 participants (2.3%) in the pitavastatin group and by 53 (1.4%) in the placebo group. Additionally, diabetes mellitus was observed in 206 participants (5.3%) taking pitavastatin and in 155 participants (4.0%) in the placebo group.